Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
CNS Tumors: early-phase trial registry
3 of 4 indexed CNS Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
CNS Tumors: 4 US clinical trials tracked, 3 recruiting.
CNS Tumors is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is ITM Solucin, running 1 of these trials.
Enrollment posture brief
Registry condition cns-tumors
OPEN 3 | RECR 75% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
CNS Tumors lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for CNS Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
CNS Tumors is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Weill Medical College of Cornell University
NCT04081701
A Study of Avutometinib for People With Solid Tumor Cancers
Memorial Sloan Kettering Cancer Center
NCT06104488
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
ITM Solucin
NCT06441331
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Hoffmann-La Roche
NCT02650401
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on CNS Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on CNS Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this CNS Tumors page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 CNS Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ITM Solucin sponsors the most CNS Tumors trials on record, review their full trial history before evaluating a specific study. See ITM Solucin's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CNS Tumors condition card totals 4 registered trials; most-linked intervention Lutetium Lu 177-Edotreotide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.